Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies

The American Journal of Medicine
R TabibiazarS G Rockson

Abstract

Extensive animal studies and a growing number of human clinical trials have now definitively demonstrated the central role of the renin-angiotensin-aldosterone system in the expression and modulation of cardiovascular disease. In contrast to the original hypothesis, the benefits of angiotensin antagonism do not emanate from the antihypertensive effect alone. Subsequent extensive investigations of angiotensin blockade suggest that the benefits of this approach may also result from the pharmacologic alteration of endothelial cell function and the ensuing changes in the biology of the vasculature. The more recent availability of direct antagonists of the AT(1) angiotensin receptor has introduced an element of doubt into this realm of clinical decision making. The receptor antagonists and the more widely studied converting-enzyme inhibitors share many endpoint attributes. Nevertheless, the partially overlapping mechanisms of action for the two classes of angiotensin antagonists confer distinct pharmacologic properties, including side effect profiles, mechanisms of action, and theoretic salutary effects upon the expression of cardiovascular disease. The current review will attempt to contrast the biology of angiotensin converting-en...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Aug 1, 1995·American Journal of Hypertension·L J DominguezJ R Sowers
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·H S KimO Smithies
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·M ItoT M Coffman
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·O Smithies, N Maeda
Jul 1, 1993·Journal of the American Society of Nephrology : JASN·A RemuzziG Remuzzi
Nov 10, 1995·Regulatory Peptides·J W Wright, J W Harding
Jan 1, 1995·Clinical and Experimental Pharmacology & Physiology. Supplement·M KohzukiK Abe
Aug 4, 1997·The American Journal of Cardiology·W LinzB A Schölkens
Jun 1, 1997·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K J WirthB A Schölkens
Sep 18, 1998·International Journal of Cardiology·V P MazayevD O Spormann

❮ Previous
Next ❯

Citations

Jul 6, 2014·Drug Discovery Today·Katarzyna RegulskaMarek Murias
Jul 16, 2002·Current Hypertension Reports·Sumeska Thavarajah, George A Mansoor
Oct 29, 2002·The American Journal of Medicine·Ernesto L Schiffrin
Oct 16, 2004·Journal of Evaluation in Clinical Practice·Takeshi MorimotoDavid W Bates
Aug 9, 2003·Expert Opinion on Drug Safety·Neil Shusterman
Feb 21, 2003·Journal of Medicinal Chemistry·Eva M Krovat, Thierry Langer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.